Page 6 - Biocon

Biocon urges govt to exempt cancer, rare-disease drugs from tax in Budget

To make cancer care more affordable in price-sensitive India, Mazumdar-Shaw said, the government must also cut import duties for high-tech instruments

CCI fines Goldman Sachs manager Rs 40 lakh over Biocon deal failure

The Competition Commission has imposed a penalty of Rs 40 lakh on the investment manager of Goldman Sachs AIF for failing to notify the regulator about the more than four-year-old deal that gives the option to buy up to 3.81 per cent stake in Biocon Biologics. The penalty was levied on Goldman Sachs (India) Alternative Investment Management Pvt Ltd (GS AIMPL), the investment manager of Goldman Sachs AIF, for a contravention of Section 6(2) of the Competition Act, which mandates prior approval for certain combinations. Under the deal, Goldman Sachs AIF Scheme-1 (GS AIF) had acquired optionally convertible debentures (OCDs) issued by Biocon Biologics. The regulator has penalised GS AIMPL for failing to notify the transaction to it and rejected the argument that the deal was done in the ordinary course of business. "Any transaction which is made with the intent of remaining invested for a relatively longer period and involves the acquisition of any additional rights (compared to the .

Ajit Mishra of Religare Broking picks Biocon, Marico as stocks to buy today

Stocks to Buy Today: Ajit Mishra of Religare Broking suggests buying Biocon shares and Marico shares. He also suggests shorting Asian Paints shares

Chandan Taparia of MOFSL recommends buying these 3 stocks on January 15

Stocks to buy today, Jan 15: Bajaj Finance share price is on the verge of a breakout from a flag and pole pattern on the daily chart with higher-than-average buying volumes

Biocon extends rally, up 6% in 2 days on HSBC, Motilal Oswal 'Buy' upgrade

Notably, Biocon share price has surged about 6 per cent in the last two sessions

Stocks to Watch, Jan 8, 2025: Tata Steel, Sobha, M&M, REC, SBI, RVNL, CESC

Stocks to Watch, Jan 8, 2025: From Tata Steel to Dr. Reddy's Labs, here is a list of stocks that will remain in focus today

Biocon Biologics marks one year as global biosimilars enterprise

It is targeting a $100 m inventory improvement by March

Biocon share rises 4% as arm gets Japan's PMDA approval for Psoriasis drug

The rise in Biocon stock was also fuelled after Jefferies upgraded the stock to 'Buy', and raised the target to Rs 400

Stocks to Watch, Jan 3, 2025: TaMo, M&M, Airtel, Avenue Supermarts, IOC

Stocks to Watch, Jan 3, 2025: From Avenue Supermarts to Tata Motors, here are few stocks that will be on investors' radar today

Religare Broking's Ajit Mishra says buy these pharma, QSR and auto stocks

Nifty Today, Stocks to Buy Today: The Nifty50 index has now entered its second week of consolidation, and current indicators suggest that this trend is likely to persist

Kiran Mazumdar gets 'Jamsetji Tata Award' for biosciences movement in India

Biocon Group Chairperson Kiran Mazumdar-Shaw was conferred the prestigious Jamsetji Tata Award by the Indian Society for Quality (ISQ) on Saturday for pioneering the biosciences movement in India. "This award holds a very special meaning to me as it is named after one of India's greatest visionaries - a man whose legacy of excellence, innovation, and nation-building continues to inspire us all. Jamsetji Tata's commitment to quality and his belief in the transformative power of industry to serve society resonate deeply with my own journey," said Mazumdar-Shaw. The Jamsetji Tata Award, instituted in 2004 by ISQ recognises business leaders who have made significant contributions to Indian society. The Award was announced at the ISQ Annual Conference 2024, held in Bengaluru. Mazumdar-Shaw received the award from Janak Kumar Mehta, President of ISQ and Chairman and Managing Director, TQM International. "This Lifetime achievement award is being presented to Kiran Mazumdar-Shaw for being

Biocon share falls 4% after USFDA issues VAI tag for Bengaluru's API unit

Biocon's Bengaluru API facility was inspected between September 23 to September 27, 2024

Biocon rises 3% after its arm gets US FDA nod for psoriasis drug YESINTEK

Biocon Biologics Ltd had previously notified on February 29, 2024, that the company had entered into a settlement and licensing agreement with Janssen

USFDA approves Biocon Biologics' biosimilar for Crohn's disease, psoriasis

YESINTEK, a monoclonal antibody, is approved for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis

Ajit Mishra of Religare Broking recommends these 3 stocks on Nov 28

The Nifty has demonstrated resilience throughout this consolidation phase, and the upcoming monthly expiry of November derivatives contracts on Thursday

Biocon Biologics, Diabetes Africa collab over nurses project in Ethiopia

Ethiopia, with a 2-3 per cent diabetes prevalence rate, ranks among the top four countries in sub-Saharan Africa for adult diabetes cases

Bioengineering is really the way we have to move forward: Mazumdar-Shaw

Says today, we are at an inflection point when it comes to technology. Up until now, we used to scratch at the surface because we couldn't really understand the mysteries of biology

Biocon share jumps 6% on USFDA's 'VAI' tag to Bengaluru facility; details

The surge in Biocon share price came after the company announced that United States Food and Drug Administration (USFDA) has classified Biocon Biologics' Biocon Park Site in Bengaluru as VAI

Will launch 3 biosimilars globally in 2-3 years: Biocon Biologics CEO & MD

Shreehas Tambe, MD & CEO, Biocon Biologics talks about refinancing, upcoming launches, and future roadmap, in a virtual interaction

Biocon Q2 results: Net loss of Rs 16 cr on high tax, revenue at Rs 3,590 cr

Biocon Ltd on Wednesday reported a consolidated net loss of Rs 16 crore for the second quarter ended September 30, 2024 on account of higher tax, based on geographical split of profits. The company had posted a net profit of Rs 126 crore for the July-September period last fiscal. Revenue from operations stood at Rs 3,590 crore in the September quarter as compared with Rs 3,462 crore in the year-ago period, Biocon Ltd said in a statement. "Biocon Group's overall Q2FY25 financial and operational performance provides a foundation for improved performance as we move into the second half of the fiscal," Biocon Group Chairperson Kiran Mazumdar-Shaw said. The group had a robust performance in the biosimilars business driven by strong market share gains in US Oncology and Insulin franchises, she noted. Syngene has returned to sequential growth and has good visibility of a pickup in momentum in the coming quarters led by its discovery services and biomanufacturing CMO business, she ...